Oral ozempic Alternative Shows Promise,Could Expand Access to Diabetes and Weight Loss Treatment
RIO DE JANEIRO,BRAZIL – A new oral medication,orforglipron,is demonstrating potential as a convenient and cost-effective alternative to injectable treatments like semaglutida (Ozempic) for type 2 diabetes and obesity,according to recent research. The tablet form of the drug is absorbed directly through the digestive tract, eliminating the need for injections and cold storage, potentially revolutionizing access to treatment, notably in regions with limited healthcare infrastructure.
Unlike semaglutida, which requires injection due to it’s rapid breakdown in the stomach, orforglipron is designed for daily administration as a tablet. clinical trials indicate that while the medication can cause transient side effects such as nausea, vomiting, constipation, and diarrhea, these effects generally do not prevent continued use. This makes it a potentially safer alternative for many patients.
The progress addresses a significant barrier to treatment for millions. Semaglutida’s injectable format necessitates cold storage and can be a source of discomfort for patients. Orforglipron’s oral delivery system bypasses these issues, offering a simpler and more accessible option. this is particularly crucial for areas facing infrastructure challenges, potentially facilitating global access to vital therapies.
Researchers anticipate the drug will be approved by 2026, with expectations for a lower cost compared to injectable options. This affordability, combined with the ease of administration, could substantially expand access for patients seeking practical weight and blood glucose management solutions. Future studies will focus on directly comparing orforglipron’s efficacy against currently approved weight loss medications.
